These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 223044

  • 1. [Hyperlipoproteinemia type IIa. Serum lipoprotein pattern as influenced by diet and clofibrate].
    Mertz DP, Suermann I, Loewer H, Schmidt GG.
    MMW Munch Med Wochenschr; 1979 Jun 08; 121(23):791-2. PubMed ID: 223044
    [No Abstract] [Full Text] [Related]

  • 2. [Influence of "prudent" diet and clofibrate upon apolipoprotein B in hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP, Suermann I, Göhmann E.
    Med Klin; 1979 Feb 23; 74(8):279-83. PubMed ID: 216895
    [Abstract] [Full Text] [Related]

  • 3. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Feb 23; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 4. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R, Müller A, Klose G, Middelhoff G, Augustin J, Haase W, Greten H.
    MMW Munch Med Wochenschr; 1978 Apr 14; 120(15):525-8. PubMed ID: 206826
    [Abstract] [Full Text] [Related]

  • 5. [Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)].
    Mertz DP, Suermann I, Göhmann E.
    MMW Munch Med Wochenschr; 1978 Aug 25; 120(34):1097-9. PubMed ID: 210375
    [Abstract] [Full Text] [Related]

  • 6. Treatment of hypercholesterolemia.
    Kane JP, Havel RJ.
    Annu Rev Med; 1986 Aug 25; 37():427-35. PubMed ID: 3518611
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum lipoprotein lipids after gemfibrozil treatment.
    Schwandt P, Weisweiler P, Neureuther G.
    Artery; 1979 Feb 25; 5(2):117-24. PubMed ID: 231950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Management of hyperlipidemias.
    Murphy BF.
    JAMA; 1979 Feb 25; 230(12):1683-91. PubMed ID: 4373590
    [No Abstract] [Full Text] [Related]

  • 15. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B, Lithell H, Gustafsson IB, Borberg J.
    Atherosclerosis; 1979 Aug 25; 33(4):457-77. PubMed ID: 228684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U, Johannes KJ.
    MMW Munch Med Wochenschr; 1976 Sep 03; 118(36):1127-30. PubMed ID: 184377
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.
    Falko JM, Witztum JL, Schonfeld G, Weidman SW, Kolar JB.
    Am J Med; 1979 Feb 03; 66(2):303-10. PubMed ID: 218451
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.